newsfilter
← Latest News
Business Wire·

ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer

Data Further Position ELAHERE to Become the New Standard of Care for Patients with FRα-Positive Platinum-Resistant Ovarian Cancer Findings to be Highlighted in Oral Presentation at ESGO Annual Congress ImmunoGen